Jazz Pharmaceuticals Presents at SLEEP 2025
Nineteen abstracts, including eleven late-breaking abstracts, underscore Jazz's leadership and extensive research in sleep medicine, and ongoing commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia.
For U.S. media and investors only
DUBLIN, May 29, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that nineteen abstracts, including eleven late-breaking abstracts will be presented at SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies (APSS) being held June 8-11, 2025, in Seattle.
Research to be presented at the meeting include dual late-breaking poster and oral presentations, which highlight the extensive Phase 4 data evaluating the effectiveness of low-sodium oxybate, Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia (IH). These presentations include the first interim results from the open-label, single arm XYLO trial that evaluated ambulatory and office blood pressure changes in patients with narcolepsy after switching from a twice-nightly high-sodium oxybate oral solution to low-sodium oxybate, Xywav. Two additional presentations share novel results from the open-label, single arm DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) trial, which assessed Xywav on multiple sleep parameters, including the first presentation of polysomnography (PSG) outcomes in adults with IH. Additional data evaluated the effectiveness and safety of Xywav in a cohort of narcolepsy patients whose doses were optimized to greater than 9 grams (with twice-nightly dosing). The Xywav label recommends a maximum nightly dose of 9 grams per night.
"Jazz prioritizes a holistic approach to patient health, continuously deepening our understanding of how to support patients with challenging sleep disorders, as well as mitigate associated comorbidities," said Kelvin Tan, MB BCh, MRCPCH, chief medical affairs officer of Jazz Pharmaceuticals. "The extensive research presented at SLEEP 2025, underscores our commitment to patient-centric care, including the development of low-sodium Xywav, which is particularly important given the impact of sodium intake and existing cardiovascular risks among patients with narcolepsy or idiopathic hypersomnia."
Additional highlights at SLEEP 2025 include:
The SLEEP 2025 abstracts are available online at sleepmeeting.org/abstract-supplements.
A full list of Jazz Pharmaceuticals' presentations follows below:
| Presentation Title |
Lead Author |
Presentation Type & Number / Session / Date & Time (PT) |
| Nocturnal Spontaneous Arousals in People With Narcolepsy and Idiopathic Hypersomnia Following Treated With Low-Sodium Oxybate |
C Ruoff |
Oral Presentation Session: LBA-02 (NON-CME), June 9, 2025, 2:15 –2:30 p.m.; Poster #: 556, Session Date/Time: June 10, 2025, 10:00 –11:45 a.m. |
| Prevalence and Severity of Sleep Inertia Among Individuals With Idiopathic Hypersomnia |
JK Alexander |
Oral Presentation Session: LBA-02 (NON-CME), June 9, 2025, 2:30 –2:45 p.m.; Poster #: 557, Session Date/Time: June 10, 2025, 10:00 –11:45 AM |
| Impact of Switching From High- to Low-Sodium Oxybate on Ambulatory Blood Pressure in Patients With Narcolepsy |
VK Somers |
Oral Presentation Session: LBA-02 (NON-CME), June 9, 2025, 2:45 –3:00 p.m.; Poster #: 554, Session Date/Time: June 10, 2025,10:00 –11:45 AM |
| Effectiveness and Safety of Low-Sodium Oxybate Dosages Greater Than 9 Grams in Study Participants With Narcolepsy |
JH Simmons |
Oral Presentation Session: LBA-02 (NON-CME), June 9, 2025, 3:00 –3:15 p.m.; Poster #: 558, Session Date/Time: June 10, 2025, 10:00 –11:45 AM |
| Effectiveness and Safety of Low-Sodium Oxybate in Participants With Narcolepsy: Results From the DUET Study |
LD Schneider |
Oral Presentation Session: O-24, June 11, 2025, 4:30 –4:45 p.m.; Poster #: 393, Session Date/Time: June 11, 2025, 10:00 –11:45 AM |
About Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution
Xywav is the only low-sodium oxybate approved by the U.S. Food and Drug Administration (FDA) for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. The FDA recognized seven years of Orphan Drug Exclusivity for Xywav for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy...
Important Safety Information for Xywav
WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE...
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families...
Contacts:
Media: Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
[email protected]
Ireland +353 1 637 2141
U.S. +1 215 867 4948
Investors: Jeff Macdonald
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
[email protected]
Ireland +353 1 634 3211
U.S. +1 650 496 2717
References:
SOURCE Jazz Pharmaceuticals plc
